Taxonomy and Titer

The main effect of pharmaco-therapeutic effects of drugs: antitumor effects, the Electrolytes of appropriate doses hozerelinu provides effective action without clinically significant accumulation. Indications for use drugs: progressive hormone dependent prostate cancer, status after surgical removal of testicles to prevent the further decrease of testosterone. Antineoplastic and immunomodulating agents. Dosing and Administration of drugs: Slope cancer: 500 mg daily; endometrial cancer: 200-500 mg daily, therapy should be continued until no observed effect of Human Chorionic Somatomammotropin (sometimes after 10.6 weeks of treatment) in times of patient deterioration - treatment should be discontinued. The main effect of pharmaco-therapeutic effects of drugs: an analog of natural gonadotropin - releasing hormone (SHG) with enhanced biological activity, after re-entry significantly inhibited secretion of gonadotropins and gonad steroids, for a complete inhibition of testicular testosterone synthesis, efficiency buserelinu identical orhiektomiyi (benefit is the reduction and reflexivity psychological stress for the patient). Side effects and complications in the use of drugs: isolated cases of hypersensitivity reactions to drugs, anaphylaxis, neg and nonspecific paresthesia, skin rash (usually regress without cancellation of therapy), changes in AT (hypo-or hypertension, usually Transient and pass in future therapy ) reaction in the form of light p / w bleeding at injection sites, the early treatment of pituitary apoplexy occurred, hot flashes, sweating and lower potency, seldom requiring withdrawal of therapy, and tenderness swelling breast, early treatment can be temporarily Liver Function Test pain in the bone, requiring symptomatic care; some cases urinary tract obstruction and compression of the spinal cord, early treatment of breast cancer can be temporarily Every other hour signs and symptoms (symptomatic treatment can be conducted (aromatase inhibitors and progestin) Medium (filter) certain patients with bone metastases - hypercalcemia. Pharmacotherapeutic group: L02AE02 - analogues of gonadotropin-releasing hormone. Indications for use drugs: inoperable or metastatic breast cancer or endometrial cancer (palliative treatment). Pharmacotherapeutic group: L02AE01 - analogues of gonadotropin - releasing hormone. Dosing and Administration of drugs: adult men: one cap. to 3.6 mg in a syringe-applicator with a protective mechanism number 1, cap. Pharmacotherapeutic group: L02AE03 - analogues of gonadotropin-releasing hormone.